MANAGEMENT

Chief Executive Officer

William J. Sibold

Bill is an accomplished leader with multi-functional international experience in the pharmaceutical, biotech and associated outsourcing industries. Bill started his career with Eli Lilly Canada in Sales. At Amgen Bill was a Product Manager in Epogen Marketing responsible for developing product strategy, tactical plans, and analytical decision-making.

In addition to his biotech and pharma experience Bill worked for one of the first Site Management Organizations in the country. ICSL operated over 50 clinical trial sites with phase I-IV trial capabilities. There, Bill led the Business Development and Sales departments.

Bill joined Biogen Idec as the Director of New Products Commercialization in 2001 where he was responsible for creating the commercial strategy and aligning stakeholder’s opinions of the early stage pipeline. Next, Bill moved to Sydney to run Biogen Idec’s Australia Asia Pacific business which included Australia, New Zealand, and several Asian countries. Bill returned to the US as the VP of Commercial Operations for the Neurology Strategic Business Unit where he oversaw Sales, Marketing and Patient Services. He relaunched Tysabri under a complicated Risk Minimization Plan mandated by the FDA and achieved significant sales growth milestones. He was promoted to Senior Vice President, US Neurology then Senior Vice President US Commercial where he oversaw Oncology, Rheumatology and Neurology (~800 employees) and a P&L of over $2.5 billion.

Bill has a MBA from Harvard University and a BA in Molecular Biophysics and Biochemistry from Yale University where he also was a member of the varsity tennis team and captain in his senior year.

Chief Science Officer

Gary D. Glick, Ph.D.

Dr. Gary D. Glick founded Lycera Corp. in 2006 and raised the seed round and series A financing for the company. He obtained his Ph.D. from Columbia University in 1988, studying organic chemistry under the direction of W. Clark Still. He then completed a National Institutes of Health postdoctoral fellowship at Harvard University where he studied bio-organic chemistry in the laboratory of Jeremy R. Knowles. In 1990, Dr. Glick joined the chemistry faculty at the University of Michigan in Ann Arbor, where he presently holds the Werner E. Bachmann chair in chemistry, is a professor in the Department of Biological Chemistry at the University of Michigan Medical School, and is a member of the training faculty for the interdepartmental Immunology and Medicinal Chemistry doctoral programs. He is also the founder and director of the Chemical Biology Doctoral Program at Michigan. Dr. Glick’s research interests are in drug discovery and development for autoimmune diseases and cancer; chemical-induced apoptosis; nucleic acid structure, folding and recognition; and molecular recognition of nucleic acids by proteins.

Dr. Glick has served and continues to serve on numerous boards and committees, including the Bioorganic & Natural Products Chemistry Study Section of the National Institutes of Health and the Scientific Advisory Board of the National Arthritis Foundation, Michigan Chapter. He serves on several editorial boards, is Editor-in-Chief of Biopolymers, a leading journal publishing in the areas of biochemistry and biophysics, and is a counselor to the American Chemical Society Division of Biological Chemistry.

Dr. Glick’s scientific contributions have been recognized with a number of different awards including, an Arthritis Investigator Award from the National Arthritis Foundation, a Junior Faculty Research Award from the American Cancer Society, a Young Investigator Award from the National Science Foundation, a Camille Dreyfus Teacher-Scholar Award, a Research Fellowship from the Alfred P. Sloan Foundation, two Research Excellence Awards from the University of Michigan, and is a Fellow of the American Association for the Advancement of Science.

Vice President of Biology

Paul S. Changelian, Ph.D.

Dr. Paul S. Changelian is an expert in autoimmune diseases, organ transplantation and kinase biology. He is a key member of Lycera’s drug discovery and development team. Prior to joining Lycera, Dr. Changelian worked for nearly twenty years as a researcher for Pfizer, in several roles, including director of inflammation biology. His lab’s chief concern was the identification of molecular targets that would lead to drugs preventing renal transplant rejection. That research culminated in 2000 with the discovery of CP-690,550, a compound that has since shown efficacy in Phase II trials for renal transplantation and is currently in Phase III trials for rheumatoid arthritis and Phase II trials for multiple sclerosis, inflammatory bowel disease, psoriasis, and dry eye. Most recently, Dr. Changelian led his own pharmaceutical consulting company. His work has been published in nearly 30 peer-reviewed publications including Science. He is also currently an adjunct assistant professor of internal medicine at the University of Michigan Medical School on the faculty at the University of Michigan Medical School.

Dr. Changelian received his doctorate in immunology from Harvard University and completed his postdoctoral studies at Washington University at St. Louis.

Vice President of Chemistry and Chemical Biology

Peter L. Toogood, Ph.D.

Dr Peter L. Toogood is an expert in immunology, inflammation, infectious diseases and cancer. He is helping to lead Lycera's efforts to develop novel small-molecule pharmaceuticals to treat autoimmune diseases. Dr. Toogood joined Lycera after working as a research scientist and manager at Parke-Davis and Pfizer. He has led teams in cancer and infectious disease drug discovery and was an inventor of the first selective cyclin-dependent kinase 4 inhibitor to enter human clinical trials. Prior to that, he was a faculty member in the Department of Chemistry at the University of Michigan. There he established a research program in natural products total synthesis and chemical biology, funded by the National Institutes of Health and the National Science Foundation. He is the author of more than 40 peer-reviewed publications and holds several patents and pending patent applications. In addition to his work at Lycera, Dr. Toogood is an adjunct professor in the University of Michigan College of Pharmacy.

Dr. Toogood completed his doctoral work at Imperial College in London and was a NATO postdoctoral fellow at Harvard University.